US to get 3rd COVID-19 vaccine, Johnson & Johnson files Emergency Use Authorization

Follow us on Google News:
 US to get 3rd COVID-19 vaccine, Johnson & Johnson files Emergency Use Authorization

Summary

  • Johnson & Johnson has applied for an Emergency Use Authorization for Janssen’s COVID-19 vaccine candidate.
  • The Company intends to distribute its COVID-19 vaccine to the US government immediately after the FDA Authorization.
  • The vaccine candidate’s Phase 3 trial data showed that it was ~66% effective in protecting against coronavirus.

Johnson & Johnson (NYSE:JNJ) updated the market that Janssen Biotech Inc has submitted an application to the US regulator for an Emergency Use Authorization (EUA) of its COVID-19 vaccine candidate.

Let us deep dive and discuss in detail:

The New Jersey-based multinational firm submitted the EUA application based on top-line efficacy and safety information from the Phase 3 ENSEMBLE clinical trial. The trial data demonstrated that a single-dose vaccine met all primary as well as major secondary endpoints. The trial data showed the vaccine was almost 66% effective in protecting against coronavirus.

Johnson & Johnson anticipates having its vaccine available for shipment immediately after the Food and Drug Administration (FDA) Authorization.

Source: © Akakshu | Megapixl.com

If the US regulator authorizes J&J’s application, it would be the 3rd COVID-19 vaccine in the US available for emergency use. Two vaccines developed by Pfizer Inc (NYSE:PFE)-BioNTech SE (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) were authorized for emergency use in December 2020.

MUST READ: Lab tests confirm BioNTech (NASDAQ: BNTX), Pfizer vaccine effective against new Covid-19 variants

Moreover, Johnson & Johnson has commenced rolling submissions with several health organizations outside the US. The Company will submit a cMAA (Conditional Marketing Authorization Application) with the EMA (European Medicines Agency) in the forthcoming weeks.

Johnson & Johnson to supply 100 million doses to the US

J&J also highlighted that the Janssen COVID-19 vaccine is compatible with the distribution channels of a standard vaccine.

On authorization by the FDA, Janssen’s COVID-19 vaccine is expected to remain stable for a minimum of two years at -4°F (-20°C). Further, the Company highlighted that the vaccine could be stored in standard refrigerators at temperatures of 36°-46°F (2°-8°C) for at least three months.

Source: © 2020 Kalkine Media Pty Ltd

Johnson & Johnson plans to ship its COVID-19 vaccine applying similar cold chain technologies that the Company uses to transport other innovative medications.

It is noteworthy to mention that the Company intends to distribute its COVID-19 vaccine to the US government immediately after the FDA authorization. J&J also anticipates supplying almost 100 million doses to the US in 1H 2021.

Janssen vaccine met primary endpoints in Phase 3 ENSEMBLE trial

On 29 January 2021, Johnson & Johnson updated the market with the top-line efficacy and safety results from the Phase 3 ENSEMBLE clinical trial. The trial results demonstrated that the investigational vaccine met all primary and secondary endpoints.

The Company notified that vaccine candidate was 72% Effective in the US and almost 66% effective overall for preventing moderate to severe symptoms of COVID-19.

ALSO READ: WHO Chief cautions over inequality amid global COVID-19 vaccine rollout

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Featured Articles

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK